PMID- 30248688
OWN - NLM
STAT- MEDLINE
DCOM- 20190610
LR  - 20190613
IS  - 1439-3522 (Electronic)
IS  - 0720-4299 (Linking)
VI  - 86
IP  - 9
DP  - 2018 Sep
TI  - [Myasthenia gravis: current status of antibody diagnostics and aspects on 
      refractory myasthenia gravis].
PG  - 551-558
LID - 10.1055/a-0624-9397 [doi]
AB  - Acquired myasthenia gravis (MG) is an autoimmune disease that leads to 
      fluctuating muscle weakness and fatigue, caused by circulating antibodies against 
      different structures of the neuromuscular junction. In most patients, antibodies 
      against acetylcholine receptor (AChR) can be detected. In a smaller proportion of 
      patients with and without AChR antibodies, antibodies to muscle-specific kinase 
      (MuSK), or related proteins such as agrin, cortactin and low-density lipoprotein 
      receptor-related protein 4 (LRP4), are present. With current therapy, most 
      patients achieve a stable condition with good quality of life and normal life 
      expectancy. Nevertheless, 10 to 15 % of patients fail to respond ad equately to 
      current therapies and are defined as refractory myasthenia gravis. Their clinical 
      course is characterized by recurrent episodes of severe, acute deterioration, 
      which sometimes appear life threatening. This article gives an overview of the 
      current state of myasthenic antibody diagnostics and recommended treatment of 
      refractory myasthenia gravis.
CI  - (c) Georg Thieme Verlag KG Stuttgart . New York.
FAU - Wenninger, Stephan
AU  - Wenninger S
AD  - Friedrich-Baur-Institut, Klinikum der Universitat Munchen.
FAU - Schoser, Benedikt
AU  - Schoser B
AD  - Friedrich-Baur-Institut, Klinikum der Universitat Munchen.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Myasthenia gravis: aktuelle Antikorperdiagnostik und Aspekte zum 
      therapierefraktaren Verlauf.
DEP - 20180924
PL  - Germany
TA  - Fortschr Neurol Psychiatr
JT  - Fortschritte der Neurologie-Psychiatrie
JID - 8103137
RN  - 0 (Autoantibodies)
SB  - IM
MH  - Autoantibodies/*analysis
MH  - Drug Resistance
MH  - Humans
MH  - Myasthenia Gravis/*diagnosis/*therapy
COIS- Keine im Hinblick auf das gegenwartige Manuskript. Dr. med. Stephan Wenninger 
      erhielt eine zweckgebundene Forschungsfinanzierung der DGM u Deutsche 
      Gesellschaft fur Muskelkranke e.V., Vortragshonorare und Reisekostenunterstutzung 
      von den Unternehmen CSL Behring, Sanofi-Genzyme, Recordati Pharma sowie Honorare 
      im Advisory Board der Firma Alexion Pharma und CSL Behring. Prof. Dr. B. Schoser 
      erhielt Vortragshonorare und Reisekostenunterstutzung von den Unternehmen CSL 
      Behring, Sanofi-Genzyme, Recordati Pharma sowie Honorare im Advisory Board der 
      Firma Alexion Pharma und CSL Behring.
EDAT- 2018/09/25 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/09/25 06:00
PHST- 2018/09/25 06:00 [entrez]
PHST- 2018/09/25 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
AID - 10.1055/a-0624-9397 [doi]
PST - ppublish
SO  - Fortschr Neurol Psychiatr. 2018 Sep;86(9):551-558. doi: 10.1055/a-0624-9397. Epub 
      2018 Sep 24.